MEI Pharma, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (39)

Latest Posts

About This Stock More About This Stock
Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Article By: ChinaBio® Today
Saturday, October 13, 2018 4:59 PM EDT
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
In this article: MEIP, BGNE
Read
Buying Stocks Below Their Cash Value
Article By: Fred Fuld
Monday, October 9, 2017 8:30 PM EDT
There are numerous risks and advantages to buying below cash stocks. To learn more about this investment strategy as well as some real life examples, read on.
In this article: GENC, BEBE, SPRT, MEIP, RUBI
Read
E MEI Pharma Signs Licensing Deal, Soars Higher
Article By: Terry Chrisomalis
Monday, August 8, 2016 10:42 PM EDT
The announcement of MEIP's license agreement with Swiss pharma group Helsinn put the stock up more than 48% premarket, ending the day up just shy of 28%.
In this article: MEIP
Read
Why MEI Pharma Is Likely To Rally Over $3 In The Next Month Or So
Video By: Scott Matusow
Thursday, May 7, 2015 11:10 AM EDT
In this video, I explain why I like the MEIP chart and why I think it will rally over $3 in the next 3 to 4 weeks .
In this video: MEIP Also: SGYP, IBB
Watch
MEI Pharma Is Oversold And Will Recover
Article By: Scott Matusow
Wednesday, April 1, 2015 12:02 PM EDT
Recently, MEI Pharma reported that its Phase II trial for Pracinostat in combination with azacitidine failed to meet its primary endpoint. However, Pracinostat has been shown to work in a 2nd line setting. With catalysts upcoming, the stock is oversold and half valued and should rally back.
In this article: MEIP, FOLD, ACAD
Read

PARTNER HEADLINES

Latest Tweets for $MEIP

No tweets yet!